Navigation Links
Semafore's SF1126 Exhibits Antitumor and Antiangiogenic Activity
Date:1/9/2008

INDIANAPOLIS, Jan. 9 /PRNewswire/ -- Semafore Pharmaceuticals Inc. today announced that a paper published in Cancer Research (2008; Vol. 68, Issue 1: 206-215) reports that SF1126, the company's lead product candidate, exhibits antitumor and antiangiogenic activity.

The paper, entitled "A Vascular Targeted Pan Phosphoinositide 3-Kinase Inhibitor Prodrug, SF1126, with Antitumor and Antiangiogenic Activity," is based on preclinical studies conducted by Semafore and collaborators at Children's Healthcare of Atlanta, Emory University School of Medicine, and M.D. Anderson Cancer Center. Phosphoinositide 3-kinase (PI3K) is a powerful pathway and an emerging cancer target for inhibition. In the studies reported, SF1126 showed favorable pharmacokinetics and pharmacodynamic effects as indicated by inhibition of downstream signaling elements both in vitro and in vivo. In addition, SF1126 displayed potent antitumor and antiangiogenic activity in vivo, in mouse models, against a variety of human cancer cell types, including prostate, breast, neuroblastoma, and glioblastoma.

SF1126 differs from other known PI3K inhibitors in that it has a homing feature designed to localize more drug in the tumor compartment. Based on the studies reported in the paper, SF1126 also significantly enhanced the activity of docetaxel in a combination regiment in a prostate cancer model.

"The data further support our belief that SF1126 is a viable pan PI3K inhibitor as we continue Phase I clinical trials," said Ed Jacobs, Semafore's president and chief executive officer. "SF1126 continues to support the paradigm shift in cancer treatment that will see the application of highly targeted therapeutic drugs that inhibit the powerful PI3K pathway."

About SF1126

SF1126 is a small molecule conjugate containing a pan-PI3K inhibitor that selectively inhibits all PI3K class IA isoforms and other key members of the PI3K superfamily, including DNA-PK and mTOR. A major fact
'/>"/>

SOURCE Semafore Pharmaceuticals Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. Semafores PI3 Kinase Inhibitor SF1126 is Active Against Tumor and Tumor Cells and Synergizes with Standard Chemotherapy Agents
2. Kosan Presents Phase 1 Data Showing Antitumor Activity and Safety Profile of Epothilone KOS-1584 at AACR/NCI/EORTC Meeting
3. Data Presented at 2007 ASH Meeting Demonstrate Activity of Forodesine HCl as a Single Agent or in Combination With Bendamustine in Certain Types of Leukemia and Lymphoma
4. CSL Behring Study in Animal Models Shows Feasibility of Developing a Half-Life Extended Recombinant FVIIa that Retains Biologic Activity
5. Celator(R) Pharmaceuticals Reports CPX-351 Shows Anti-Cancer Activity in Leukemia Patients
6. Post-Hoc Data Show Daily Activity Participation, Independence and Sleep Quality Improved in Adults with Moderate to Severe Rheumatoid Arthritis After Treatment with ORENCIA(R) (Abatacept)
7. Roches Investigational Polymerase Inhibitor, Combined with PEGASYS(R) and COPEGUS(TM), Shows Potent Antiviral Activity in Treatment of Chronic Hepatitis C at Four Weeks
8. Telik Announces Preclinical Data Demonstrating Anti-Cancer Activity of Dual Inhibitors of Aurora Kinase and VEGFR2
9. Interim Phase 2 Data for Exelixis XL880 Show Anti-Tumor Activity in Papillary Renal Cell Cancer
10. BiPar Announces Preclinical Data Demonstrating Anti-Tumor Activity With BSI-401, Its Second-Generation PARP Inhibitor
11. Human Genome Sciences Presents New Data Showing Anti-Tumor Activity And Safety Of Trail Receptor Antibodies In Combination With Chemotherapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2009)... Axsun Technologies, Inc., a wholly-owned subsidiary of Volcano ... development and successful testing of a novel integrated light ... proprietary optical engine design raises the bar on imaging ... swept source OCT light sources. This approach to ...
(Date:12/4/2009)... Northwest Biotherapeutics, Inc. ("NWBT" or the "Company") (OTC ... and Trademark Office has allowed its patent application on ... the manufacture of the Company,s DCVax® therapeutic cancer vaccines. ... very high concentration of dendritic cells (which are the ...
(Date:12/3/2009)... Calif. and STATE COLLEGE, Pa., Dec. 3 ... of an agreement to provide extended bioinformatics genomics ... projects performed at Ambry. ,, (Logo: ... Ambry,s CSO said, "Our team at Ambry has ...
Breaking Medicine Technology:Axsun Technologies, A Wholly-Owned Subsidiary of Volcano Corporation, Announces Breakthrough Integrated Light Source Architecture for Optical Coherence Tomography (OCT) Imaging 2Axsun Technologies, A Wholly-Owned Subsidiary of Volcano Corporation, Announces Breakthrough Integrated Light Source Architecture for Optical Coherence Tomography (OCT) Imaging 3Axsun Technologies, A Wholly-Owned Subsidiary of Volcano Corporation, Announces Breakthrough Integrated Light Source Architecture for Optical Coherence Tomography (OCT) Imaging 4Axsun Technologies, A Wholly-Owned Subsidiary of Volcano Corporation, Announces Breakthrough Integrated Light Source Architecture for Optical Coherence Tomography (OCT) Imaging 5Northwest Biotherapeutics Receives Approval of US Patent for Cost Saving Automation of High-Concentration DCVax(R) Manufacturing 2Northwest Biotherapeutics Receives Approval of US Patent for Cost Saving Automation of High-Concentration DCVax(R) Manufacturing 3Northwest Biotherapeutics Receives Approval of US Patent for Cost Saving Automation of High-Concentration DCVax(R) Manufacturing 4Northwest Biotherapeutics Receives Approval of US Patent for Cost Saving Automation of High-Concentration DCVax(R) Manufacturing 5Ambry Genetics and SoftGenetics Form Exclusive Alliance for Extended Bioinformatics Support for Next Generation Sequencing Projects 2Ambry Genetics and SoftGenetics Form Exclusive Alliance for Extended Bioinformatics Support for Next Generation Sequencing Projects 3Obesity Contributes to Rapid Cartilage Loss 51575 1Obesity Contributes to Rapid Cartilage Loss 51575 2Obesity Contributes to Rapid Cartilage Loss 51575 3Obesity Contributes to Rapid Cartilage Loss 51575 4Brazil proves developing countries can use generic medicines to fight HIV AIDS epidemic 51571 1Brazil proves developing countries can use generic medicines to fight HIV AIDS epidemic 51571 2Brazil proves developing countries can use generic medicines to fight HIV AIDS epidemic 51571 3Women 26apos 3Bs Health Expert Dr Susan Lark Featured on Searchbodydetox com 51566 1Women 26apos 3Bs Health Expert Dr Susan Lark Featured on Searchbodydetox com 51566 2
... Dimes Grantee Offers Hope for Treatment of,Children, WHITE ... successfully prevented a rare craniofacial birth defect in,mice and ... according,to new research funded in part by the March ... in the journal Nature Medicine,demonstrates the potential for translating ...
... Investments of $81.4 Million, RICHMOND, Calif., Feb. 5 ... quarter and year-end,financial results and accomplishments and provided an outlook ... 2007, Sangamo reported a,consolidated net loss of $6.7 million, or ... or $0.26 per share, for the same period in 2006.,As ...
Other Medicine Technology:Molecular Therapy Succeeds in Preventing Craniofacial Birth Defect in Mice 2Sangamo BioSciences Reports 2007 Fourth Quarter and Year-End Financial Results 2Sangamo BioSciences Reports 2007 Fourth Quarter and Year-End Financial Results 3Sangamo BioSciences Reports 2007 Fourth Quarter and Year-End Financial Results 4Sangamo BioSciences Reports 2007 Fourth Quarter and Year-End Financial Results 5Sangamo BioSciences Reports 2007 Fourth Quarter and Year-End Financial Results 6Sangamo BioSciences Reports 2007 Fourth Quarter and Year-End Financial Results 7Sangamo BioSciences Reports 2007 Fourth Quarter and Year-End Financial Results 8
(Date:12/7/2009)... Dec. 7 Patricia Scheller, CEO of Prescient ... Galen Institute,s "The Value of Innovation in Health Care" ... 9th in Washington DC at the Columbus Club at ... public policy research organization focusing on health and tax ... the Galen Institute,s conference," said Ms. Scheller. "As the ...
(Date:12/7/2009)... chairman of the board of directors for PerfectServe, a clinical ... nationwide. , ... Knoxville, Tenn. ... named executive chairman of the board of directors for ... in hospitals and practices nationwide. , , , , ,Barduson ...
(Date:12/7/2009)... RATON, Fla., Dec. 7 With more ... all-natural herbal and homeopathic remedies for people and ... as their PR firm of record. The company,s ... PetAlive ( www.PetAlive.com ), provide complete lines of ... wellness - naturally. ,, "Our publicity will ...
(Date:12/7/2009)... research. , ... Phoenix, AZ (PRWEB) December 7, ... cure for spinal cord injury: The online retailer of medical ... 45,000 products., , ,Cure Medical is a forward-thinking manufacturer of catheters. ... cord injury, the company donates 10 percent of all of their ...
(Date:12/7/2009)... may suffer from more emotional and behavioral difficulties when ... girls struggling the most when a parent is deployed ... Researchers found that having a parent deployed for a ... who has struggled with emotional problems were important factors ... to the study published online by the journal ...
Breaking Medicine News(10 mins):Health News:Prescient Medical, Inc. CEO Patricia Scheller to Speak at 'The Value of Innovation in Health Care,' a Galen Institute Conference 2Health News:Gene Barduson Named Chairman of PerfectServe Board of Directors 2Health News:Native Remedies and PetAlive.com Hires TransMedia Group to Herald Herbal for People and Pets 2Health News:Online Medical Supply Superstore Adds Cure Catheters to Product Mix 2Health News:Military children face more emotional challenges as parental deployments grow longer, study finds 2Health News:Military children face more emotional challenges as parental deployments grow longer, study finds 3
... an antiepileptic drug, is one of the several prescription ... ,Dispensing errors are often a result of miscommunication, ... and confusion between drugs with similar names.// ,It ... an interruption in treatment because it could lead to ...
... the presence of cancer cells beneath layers skin, blood ... bottle-top sized microcavity laser developed by the US department of ... without cutting large amounts of tissue.// ,This device could ... present and was able to distinguish between normal human brain ...
... study was conducted with 400,000 people from nine countries, ... consumption of fiber and presented at an International Conference ... important in reducing cancer of the colon and rectum. ... all cancers in the developed world are associated with ...
... According to a research presented during the American Academy of ... brains young. Women who walk regularly are less likely to ... function that can come with aging.// ,In the study, ... of about a half mile per week, while the most ...
... techniques are being developed on a daily basis. One of ... those suffering from a degenerative eye condition. This degenerative condition ... fluid, causing scarring and loss of vision. ,Eye specialists ... Therapy, which has a lower risk rate of damaging the ...
... on individuals with type 1 diabetes reveal that they have ... reach their teens. ,The findings were based on study ... from 12 to 21 years, without type 1 diabetes. It ... the arteries regardless of body weight, family history, smoking and ...
Other Medicine News:
The CGVL vitrectomy contact glass was designed by Rol, Fankhauser et al. for photodisruptive YAG laser procedures in the posterior vitreous....
For newly born children 10 mm internal diameter of the cornea part. Designed to work with argon/YAG Lasers....
... uses a classical distance-independent measuring principle which ... The size of the mire image is ... and the measured object; 2. The resulting ... the Ophthalmometer and the measured object; 3. ...
... a Windows-based image capture and management system ... fluorescent and ICG Angiography images. It interfaces ... also obtain images from any ophthalmic device ... RI captures high quality colour Retinal Images ...
Medicine Products: